abobotulinumtoxinA (Dysport®/Azzalure®): primary results of the APPEAL noninterven-tional study. Aesthetic Plast Surg. 2018;42(6):1672-1680.
7. Galderma UK. Azzalure, 125 Speywood units, powder for solution for injection. Summary of product characteristics. 2019.
8. Ipsen Biopharmaceuticals Inc. Dysport® (abobotulinumtoxinA) for injection, for intramuscular use. Prescribing infor-mation. 2019.
9. Nestor M, Cohen JL, Landau M, et al. Onset and duration of abobotulinumtoxinA for aesthetic use in the upper face: a systematic literature review. J Clin Aesthet Dermatol. 2020;13:E56-E83.
10. Flynn T. Botulinum toxin: examining duration of effect in facial aesthetic applications. Am J Clin Dermatol. 2010;11(3):183-199
11. Field M, Splevins A, Picaut P, et al AbobotulinumtoxinA (Dysport®), onabotulinumtoxinA (Botox®), and incobotuli-numtoxinA (Xeomin®) neurotoxin content and potential implications for duration of response in patients. Toxins (Basel). 2018;10(12):535.
12. Joseph JH, Eaton LL, Robinson J, et al. Does increasing the dose of Abobotulinumtoxina impact the duration of effec-tiveness for the treatment of moderate to severe glabellar lines? J Drugs Dermatol. 2016;15(12):1544- 1549.
13. Kerscher M, Fabi S, Fischer T, et al. IncobotulinumtoxinA demonstrates safety and prolonged duration of effect in a dose-ranging study for glabellar lines. J Drugs Dermatol. 2020;19(10):985-991.
14. Kane MAC, Brandt F, Rohrich RJ, et al. Evaluation of variable-dose treatment with a new U.S. Botulinum Toxin Type A (Dysport) for correction of moderate to severe glabellar lines: results from a phase III, randomized, double-blind, placebo-controlled study. Plast Reconstr Surg. 2009;124:1619-1629.
15. Kane MA, Monheit G. The practical use of abobotulinumtoxinA in aesthetics. Aesthet Surg J. 2017;37:S12-S19.
16. Nestor M, Ablon G, Pickett A. Key parameters for the use of abobotulinumtoxinA in aesthetics: onset and duration. Aesthet Surg J. 2017;37:S20-S31.
17. Schlessinger J, Monheit G, Kane MA, Mendelsohn N. Time to onset of response of Abobotulinumtoxina in the treatment of glabellar lines: a subset analysis of phase 3 clinical trials of a new botulinum toxin type A. Dermatol Surg. 2011;37(10):1434-1442.
18. Brandt F, Swanson N, Baumann L, Huber B. Randomized, placebo-controlled study of a new botulinum toxin type a for treatment of glabellar lines: efficacy and safety. Dermatol Surg. 2009;35(12):1893-18901.
19. Baumann L, Brandt FS, Kane MA, Donofrio LM. An analysis of efficacy data from four phase III studies of botulinum neurotoxin type A-ABO for the treatment of glabellar lines. Aesthet Surg J. 2009;29(6 Suppl):S57-S65.
20. Monheit G, Lin X, Nelson D, Kane M. Consideration of muscle mass in glabellar line treatment with botulinum toxin type A. J Drugs Dermatol. 2012;11(9):1041-1045.
21. Polacco MA, Singleton AE, Barnes CH, et al. A double-blind, randomized clinical trial to determine effects of increasing doses and dose-response relationship of incobotulinumtoxinA in the treatment of glabellar rhytids. Aesthet Surg J. 2020;28:sjaa220.
22. Pellett S, Bradshaw M, Tepp WH, et al. The light chain defines the duration of action of Botulinum toxin serotype A sub-types. mBio. 2018;9(2):e00089-18.
23. Smit R, Gubanova E, Kaufman J, et al. Patient satisfaction with abobotulinumtoxinA for aesthetic use in the upper face: a systematic literature review and post-hoc analysis of the APPEAL study. J Clin Aesthet Dermatol. 2021;14(2):E69–E88.
7. Galderma UK. Azzalure, 125 Speywood units, powder for solution for injection. Summary of product characteristics. 2019.
8. Ipsen Biopharmaceuticals Inc. Dysport® (abobotulinumtoxinA) for injection, for intramuscular use. Prescribing infor-mation. 2019.
9. Nestor M, Cohen JL, Landau M, et al. Onset and duration of abobotulinumtoxinA for aesthetic use in the upper face: a systematic literature review. J Clin Aesthet Dermatol. 2020;13:E56-E83.
10. Flynn T. Botulinum toxin: examining duration of effect in facial aesthetic applications. Am J Clin Dermatol. 2010;11(3):183-199
11. Field M, Splevins A, Picaut P, et al AbobotulinumtoxinA (Dysport®), onabotulinumtoxinA (Botox®), and incobotuli-numtoxinA (Xeomin®) neurotoxin content and potential implications for duration of response in patients. Toxins (Basel). 2018;10(12):535.
12. Joseph JH, Eaton LL, Robinson J, et al. Does increasing the dose of Abobotulinumtoxina impact the duration of effec-tiveness for the treatment of moderate to severe glabellar lines? J Drugs Dermatol. 2016;15(12):1544- 1549.
13. Kerscher M, Fabi S, Fischer T, et al. IncobotulinumtoxinA demonstrates safety and prolonged duration of effect in a dose-ranging study for glabellar lines. J Drugs Dermatol. 2020;19(10):985-991.
14. Kane MAC, Brandt F, Rohrich RJ, et al. Evaluation of variable-dose treatment with a new U.S. Botulinum Toxin Type A (Dysport) for correction of moderate to severe glabellar lines: results from a phase III, randomized, double-blind, placebo-controlled study. Plast Reconstr Surg. 2009;124:1619-1629.
15. Kane MA, Monheit G. The practical use of abobotulinumtoxinA in aesthetics. Aesthet Surg J. 2017;37:S12-S19.
16. Nestor M, Ablon G, Pickett A. Key parameters for the use of abobotulinumtoxinA in aesthetics: onset and duration. Aesthet Surg J. 2017;37:S20-S31.
17. Schlessinger J, Monheit G, Kane MA, Mendelsohn N. Time to onset of response of Abobotulinumtoxina in the treatment of glabellar lines: a subset analysis of phase 3 clinical trials of a new botulinum toxin type A. Dermatol Surg. 2011;37(10):1434-1442.
18. Brandt F, Swanson N, Baumann L, Huber B. Randomized, placebo-controlled study of a new botulinum toxin type a for treatment of glabellar lines: efficacy and safety. Dermatol Surg. 2009;35(12):1893-18901.
19. Baumann L, Brandt FS, Kane MA, Donofrio LM. An analysis of efficacy data from four phase III studies of botulinum neurotoxin type A-ABO for the treatment of glabellar lines. Aesthet Surg J. 2009;29(6 Suppl):S57-S65.
20. Monheit G, Lin X, Nelson D, Kane M. Consideration of muscle mass in glabellar line treatment with botulinum toxin type A. J Drugs Dermatol. 2012;11(9):1041-1045.
21. Polacco MA, Singleton AE, Barnes CH, et al. A double-blind, randomized clinical trial to determine effects of increasing doses and dose-response relationship of incobotulinumtoxinA in the treatment of glabellar rhytids. Aesthet Surg J. 2020;28:sjaa220.
22. Pellett S, Bradshaw M, Tepp WH, et al. The light chain defines the duration of action of Botulinum toxin serotype A sub-types. mBio. 2018;9(2):e00089-18.
23. Smit R, Gubanova E, Kaufman J, et al. Patient satisfaction with abobotulinumtoxinA for aesthetic use in the upper face: a systematic literature review and post-hoc analysis of the APPEAL study. J Clin Aesthet Dermatol. 2021;14(2):E69–E88.
AUTHOR CORRESPONDENCE
John Joseph MD drjohnjoseph@sbcglobal.net
